Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.

ABSTRACT:

Introduction

Dulaglutide (Dula) is a once-weekly glucagon-like peptide-1 receptor agonist that efficiently reduces the level of glycated hemoglobin (HbA1c) in patients with type 2 diabetes (T2D). However, the durability of the glucose-lowering effect of the first injection of Dula (1st Dula) remains unclear.

Methods

This study had a retrospective, single-center, and single-arm design in a clinical setting and was conducted between April 2016 and March 2017. We investigated the changes and fluctuations in glucose level in 15 patients with T2D using a continuous glucose monitor, from 1 day before the first administration of Dula to 6 days thereafter.

Results

The mean glucose levels decreased significantly from 1 day before 1st Dula up to 5 days thereafter, whereas the s

SUBMITTER: Matsushita M 

PROVIDER: S-EPMC6167306 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature